Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.48
Nov 16 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
626.92M
Enterprise Value
291.59M
Income
-46.26M
Sales
0.00M
Book/sh
4.00
Cash/sh
4.01
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
21
IPO
Dec 16, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.87
P/C
1.86
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
33.72
Current Ratio
33.72
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.83
EPS next Y
-1.00
EPS next Q
-0.19
EPS this Y
19.54%
EPS next Y
-39.82%
EPS next 5Y
9.33%
EPS past 3/5Y
-12.81% -43.32%
Sales past 3/5Y
- -
EPS Y/Y TTM
-5.65%
Sales Y/Y TTM
-
EPS Q/Q
20.88%
Sales Q/Q
-
Insider Own
17.71%
Insider Trans
0.00%
Inst Own
73.99%
Inst Trans
47.44%
ROA
-25.28%
ROE
-26.95%
ROIC
-13.77%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-7.07%
SMA50
-22.80%
SMA200
-22.28%
Trades
Shs Outstand
83.81M
Shs Float
68.97M
52W High
15.10 -50.46%
52W Low
3.78 97.88%
Volatility
7.04% 7.95%
ATR (14)
0.65
RSI (14)
39.60
Beta
0.31
Rel Volume
0.00
Avg Volume
1.47M
Volume
0
Perf Week
-12.72%
Perf Month
-6.27%
Perf Quarter
-36.66%
Perf Half Y
-16.80%
Perf YTD
43.02%
Perf Year
77.67%
Perf 3Y
68.09%
Perf 5Y
-
Perf 10Y
-
Prev Close
7.48
Price
7.48
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$24.05
Implied Upside
+221.5%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 22, 2026Initiated
NNeedham
Buy$21+180.7%
Jun 18, 2026Initiated
BAC logoBBofA Securities
Buy$27+261.0%
Mar 25, 2026Initiated
MS logoMMorgan Stanley
Overweight$20+167.4%
Mar 09, 2026Initiated
CCitizens
Mkt Outperform$23+207.5%
Feb 09, 2026Initiated
MFG logoMMizuho
Outperform$14+87.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rachman Ilya MCEO and ChairmanDec 10 '25Buy6.677464,9761,141,683Dec 10 06:49 PM
Morris Gabriel SCFODec 10 '25Buy6.587705,067291,429Dec 10 06:47 PM
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
M.D.Dr. Ilya Rachman M.B.A.
PresidentMr. Gabriel Morris B.A.
MSEDr. Vladimir P. Torchilin D.Sc.
M.D.Dr. Graham Ross FFPM
Ph.D.Dr. David Marks MBBS